Oruka Therapeutics annual operating income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Oruka Therapeutics Operating Income Growth & History (ORKA)
Oruka Therapeutics's operating income was −$122.1M for fiscal 2025.
View full Oruka Therapeutics company overviewOruka Therapeutics annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$122.1M | −$33.9M | — |
| 2024 | 2024-12-31 | −$88.1M | −$80.8M | — |
| 2023 | 2023-12-31 | −$7.3M | $3.3M | — |
| 2022 | 2022-12-31 | −$10.6M | $8.7M | — |
| 2021 | 2021-12-31 | −$19.3M | −$9.6M | — |
| 2020 | 2020-12-31 | −$9.8M | −$4.0M | — |
| 2019 | 2019-12-31 | −$5.8M | $2.3M | — |
| 2018 | 2018-12-31 | −$8.1M | $10.6M | — |
| 2017 | 2017-12-31 | −$18.7M | −$2.1M | — |
| 2016 | 2016-12-31 | −$16.6M | −$5.2M | — |
| 2015 | 2015-12-31 | −$11.5M | −$1.8M | — |
| 2014 | 2014-12-31 | −$9.7M | −$2.8M | — |
| 2013 | 2013-12-31 | −$6.9M | −$2.6M | — |
| 2012 | 2012-12-31 | −$4.3M | $3.0M | — |
| 2011 | 2011-12-31 | −$7.4M | $1.8M | — |
| 2010 | 2010-12-31 | −$9.2M | — | — |
Oruka Therapeutics quarterly operating income
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$50.1M | −$21.7M | — |
| Q1 2026 | 2026-03-31 | −$36.4M | −$11.3M | — |
| Q4 2025 | 2025-12-31 | −$34.4M | $268,000 | — |
| Q3 2025 | 2025-09-30 | −$34.1M | −$4.7M | — |
| Q2 2025 | 2025-06-30 | −$28.4M | −$6.9M | — |
| Q1 2025 | 2025-03-31 | −$25.1M | −$22.6M | — |
| Q4 2024 | 2024-12-31 | −$34.7M | −$33.1M | — |
| Q3 2024 | 2024-09-30 | −$29.4M | −$27.5M | — |
| Q2 2024 | 2024-06-30 | −$21.5M | −$19.5M | — |
| Q1 2024 | 2024-03-31 | −$2.5M | −$686,000 | — |
| Q4 2023 | 2023-12-31 | −$1.6M | −$42,000 | — |
| Q3 2023 | 2023-09-30 | −$1.9M | $615,000 | — |
| Q2 2023 | 2023-06-30 | −$2.0M | $1.2M | — |
| Q1 2023 | 2023-03-31 | −$1.8M | $1.5M | — |
| Q4 2022 | 2022-12-31 | −$1.5M | $4.1M | — |
| Q3 2022 | 2022-09-30 | −$2.6M | $2.2M | — |
| Q2 2022 | 2022-06-30 | −$3.2M | $1.6M | — |
| Q1 2022 | 2022-03-31 | −$3.3M | $825,000 | — |
| Q4 2021 | 2021-12-31 | −$5.7M | −$554,000 | — |
| Q3 2021 | 2021-09-30 | −$4.7M | −$2.7M | — |
| Q2 2021 | 2021-06-30 | −$4.8M | −$3.5M | — |
| Q1 2021 | 2021-03-31 | −$4.1M | −$2.8M | — |
| Q4 2020 | 2020-12-31 | −$5.1M | −$3.8M | — |
| Q3 2020 | 2020-09-30 | −$2.0M | −$743,000 | — |
| Q2 2020 | 2020-06-30 | −$1.3M | $198,000 | — |
| Q1 2020 | 2020-03-31 | −$1.3M | $441,000 | — |
| Q4 2019 | 2019-12-31 | −$1.3M | $249,000 | — |
| Q3 2019 | 2019-09-30 | −$1.2M | $415,000 | — |
| Q2 2019 | 2019-06-30 | −$1.5M | $648,000 | — |
| Q1 2019 | 2019-03-31 | −$1.8M | $992,000 | — |
| Q4 2018 | 2018-12-31 | −$1.5M | $2.8M | — |
| Q3 2018 | 2018-09-30 | −$1.7M | $2.8M | — |
| Q2 2018 | 2018-06-30 | −$2.2M | $3.4M | — |
| Q1 2018 | 2018-03-31 | −$2.8M | $1.6M | — |
| Q4 2017 | 2017-12-31 | −$4.3M | −$5,000 | — |
| Q3 2017 | 2017-09-30 | −$4.5M | $237,000 | — |
| Q2 2017 | 2017-06-30 | −$5.6M | −$1.6M | — |
| Q1 2017 | 2017-03-31 | −$4.4M | −$713,000 | — |
| Q4 2016 | 2016-12-31 | −$4.3M | −$1.1M | — |
| Q3 2016 | 2016-09-30 | −$4.7M | −$1.9M | — |
| Q2 2016 | 2016-06-30 | −$3.9M | −$1.2M | — |
| Q1 2016 | 2016-03-31 | −$3.7M | −$924,000 | — |
| Q4 2015 | 2015-12-31 | −$3.2M | −$563,000 | — |
| Q3 2015 | 2015-09-30 | −$2.8M | −$532,000 | — |
| Q2 2015 | 2015-06-30 | −$2.7M | −$313,000 | — |
| Q1 2015 | 2015-03-31 | −$2.7M | −$354,000 | — |
| Q4 2014 | 2014-12-31 | −$2.6M | $335,000 | — |
| Q3 2014 | 2014-09-30 | −$2.3M | −$560,000 | — |
| Q2 2014 | 2014-06-30 | −$2.4M | −$1.2M | — |
| Q1 2014 | 2014-03-31 | −$2.4M | −$1.3M | — |
| Q4 2013 | 2013-12-31 | −$2.9M | −$2.1M | — |
| Q3 2013 | 2013-09-30 | −$1.7M | −$797,000 | — |
| Q2 2013 | 2013-06-30 | −$1.2M | −$53,000 | — |
| Q1 2013 | 2013-03-31 | −$1.1M | $336,000 | — |
| Q4 2012 | 2012-12-31 | −$840,000 | $794,000 | — |
| Q3 2012 | 2012-09-30 | −$928,000 | $893,000 | — |
| Q2 2012 | 2012-06-30 | −$1.1M | $559,000 | — |
| Q1 2012 | 2012-03-31 | −$1.4M | $796,000 | — |
| Q4 2011 | 2011-12-31 | −$1.6M | — | — |
| Q3 2011 | 2011-09-30 | −$1.8M | $285,000 | — |
| Q2 2011 | 2011-06-30 | −$1.7M | $565,000 | — |
| Q1 2011 | 2011-03-31 | −$2.2M | — | — |
| Q3 2010 | 2010-09-30 | −$2.1M | — | — |
| Q2 2010 | 2010-06-30 | −$2.3M | — | — |
Oruka Therapeutics operating income trends
Over the last five fiscal years, Oruka Therapeutics's operating income decreased from −$9.8M to −$122.1M, a change of −$112.3M. The latest reported quarter, Q2 2026, shows −$50.1M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oruka Therapeutics source filings ↗Community posts
Oruka’s psoriasis study supports planned Phase 3 trials after strong skin clearance
Oruka ($ORKA) reported positive 16-week results for ORKA-001 in the randomized Phase 2b EVERLAST-B psoriasis study. Among 46 patients assigned the highest dose, 61% achieved complete skin clearance, compared with none of 47 placebo recipien ...
